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ABSTRACT 
 
Purpose: The tumor immune microenvironment plays a crucial role in the 
development and progression of cancer. Sarcomas are a group of heterogeneous 
soft tissue malignancies that are often treated with radiotherapy as a part of the 
treatment concept. There is increasing evidence that radiotherapy leads to 
alterations in the tumor microenvironment, particularly with respect to the immune 
infiltrate. The present study has been carried out to develop a better understanding 
of such changes following radiotherapy.  
Experimental Design: We retrospectively analyzed the expression of 35 immune 
response-related genes by qRT-PCR analysis and immunohistochemistry on paired 
formalin-fixed paraffin-embedded tumor samples from 38 sarcoma patients before 
and after radiotherapy.  
Results: We observed that radiotherapy results in a significant upregulation of 
several immune effectors and cancer-testis antigens and a concomitant 
downregulation of immune suppressors, indicating that radiotherapy may support the 
immune defense in sarcomas.  
Conclusions: These novel findings may have implications for the design of 
therapeutic regimens which exploite the immune system in sarcoma patients by 
combining standard radiotherapy with immunotherapeutic strategies. 
Translational Relevance 
Sarcomas are cancers with low incidence but high mortality, which are often treated 
with radiotherapy. However, very little is known about the impact of radiotherapy on 
the quality of the tumor-associated immune infiltrate in human sarcomas. The current 
study set out to investigate such changes using paired tumor samples before and 
after radiotherapy from a cohort of 38 sarcoma patients. Our findings demonstrate 
that radiotherapy may groom the local tumor microenvironment by promoting an 
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intratumoral immune effector signature in patients who survived for three years or 
more following radiotherapy. Furthermore, radiotherapy resulted in upregulated 
expression of MHC class I molecules and cancer-testis antigen. This knowledge 
argues for combining radiotherapy with immunotherapy as a novel modality for the 
treatment of sarcoma.  
 
INTRODUCTION 
 
Sarcomas are a heterogeneous group of malignant tumors of mesenchymal origin. 
They can arise anywhere in the bone, cartilage, fat, muscle, blood vessels, or other 
connective or supportive tissue (1). Sarcomas comprise 1% of all adult cancers and 
about 15% of all childhood cancers there, with high mortality and metastatic potential 
(2). There is clear evidence from patients and preclinical models that the immune 
system can control the development of malignancies, a concept termed tumor 
immunoediting and immunosurveillance (3). Moreover, spontaneous tumor-specific 
immunity can be detected in cancer patients and in tumor-bearing mice (4, 5). The 
targets of such responses are usually tumor-associated antigens, of which the group 
of cancer-testis (CT) antigens is a prominent representative (6). CT-antigens are 
especially interesting because they are highly immunogenic and as their name 
suggests, their expression is restricted to germ cells and cancer cells. More than 100 
CT genes are known to date (7, 8). However, when tumor-specific immunity fails to 
eliminate cancer, it has proven very difficult to boost this response such that tumor 
control is achieved. The adaptive arm of the immune response consists of T and B 
lymphocytes, including antibodies, CD8+ T cells that recognize tumor antigens 
presented by MHC class I (MHC-I) molecules on tumor cells (9) are thought to be 
major effectors. Natural killer (NK) cells, which represent the innate immune system, 
may also mediate antitumor effects by direct cytotoxicity towards malignant cells that 
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express low levels of MHC-I and by producing immunostimulatory cytokines such as 
IFN-γ (10). Immune effector functions, however, are hampered by an 
immunosuppressive environment, which is created by the tumor and to which FoxP3+ 
regulatory T cells as well as myeloid cells contribute through a variety of mechanisms 
including TGFβ, arginase-1 and IL-10 (11-13). The tumor microenvironment 
presumably significantly influences the outcome of conventional cancer therapies 
(14, 15). Human sarcomas are treated by radiotherapy, chemotherapy and/or 
surgery (16). Recent evidence suggests that both radio- and chemotherapy result in 
the mobilization of innate and adaptive immunity (17-19), but very little is known 
about the impact of radiotherapy on the immune infiltrate in human sarcomas. We 
investigated the effect of radiotherapy on the tumor microenvironment in sarcoma 
patients using paired biopsies that were collected before and after radiotherapy from 
38 sarcoma patients. Upon radiotherapy we found an increase of many cell types 
and molecules that are characteristic for protective immunity, whereas those 
associated with immunoregulation were often downregulated. Furthermore, we found 
a relatively high expression of immune effectors and low expression of immune 
suppressors after radiotherapy in those patients who survived for three years or more 
after radiotherapy in comparison to those who survived for less than three years and 
died. Our results justify further investigating whether a combination of radiotherapy 
and immune stimulation results in a better clinical outcome than either therapy alone.  
 
MATERIALS AND METHODS 
 
Patient material 
Formalin-fixed, paraffin-embedded (FFPE) paired tumor samples were collected from 
a cohort of 38 sarcoma patients before and after radiotherapy. Tumor samples were 
retrieved from the archives of the Department of Pathology, University Hospital 
Zurich. The samples after radiotherapy were obtained from planned resection and 
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the time points of collection following radiotherapy varied between 1-89 days 
(Supplementary Table S1).  Patients with non-metastatic disease and only those 
patients who received neo-adjuvant radiotherapy before surgery as a part of their 
standard treatment regimen were included in the study. The patients were treated by 
standard photon-radiotherapy and received a cumulative dose of 40-60 Gy (2 Gy per 
treatment). An overview of the sarcoma subtypes, cumulative radiation dose, 
percentage of dead cells following radiotherapy and clinical outcome is given in 
Table 1. The ethics committee "Ethical Committee of the Canton of Zurich" 
specifically approved this study (EK-2011-0224/0). For the present study, all relevant 
data were retrieved from the computerized database of the Department of Pathology, 
University Hospital Zurich and transferred into a separate anonymous database. 
Fifteen patient samples from our previous work overlapped in the current study (17), 
but were specifically approved under the study (EK-2011-0224/0) All patients signed 
the informed consent form in accordance with the declaration of Helsinki and were 
given a unique code, thus protecting the patient identity.  
 
RNA isolation and reverse transcription 
Three punches (0.6 mm diameter) were randomly taken from each of the FFPE 
blocks using a tissue arrayer MTA-1 (Beecher Instruments). Deparaffinization was 
performed in 300 µL elution buffer (1 M Tris pH 8, 0.5 M EDTA pH 8, 20% SDS (all 
Ambion), ultrapure water (Sigma)) at 95 °C for 10 min on a shaker followed by 
centrifugation at 4°C, 14’000 rpm for 10 min, followed by digestion with 3 μL of 
Proteinase K (18 +/- 4 mg/mL, Roche) at 55°C for 72 h. The samples were then 
centrifuged at 4°C, 14’000 rpm for 2 min. The supernatants (250 µL) were transferred 
into fresh tubes and 750 µL TriZol LS reagent (Invitrogen) was added to each sample 
while vortexing followed by homogenization by centrifugation at 4°C, 14’000 rpm for 
2 min using QIA-shredder columns. This was followed by RNA purification using 
phenol and chloroform. Two hundred µL of chloroform was added to each flow-
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through with mild vortexing, followed by incubation at room temperature for 5 min 
until the two phases separated, followed by centrifugation at 4°C, 14’000 rpm for 15 
min. The upper aqueous phase containing the RNA was transferred into a new tube, 
20 µg glycogen (Invitrogen) was added followed by the precipitation of RNA by 
adding 0.5 mL isopropanol (99.9% v/v, Kantonsapotheke Zürich). Samples were 
incubated at room temperature for 15 min and then centrifuged at 4°C, 14’000 rpm 
for 20 min. The supernatant was removed and the pellet was washed with 1 mL 75% 
ethanol (Merck), air-dried, dissolved in RNase free water (Sigma) and digested with 
80 U/mL DNAse I (New England Biolabs) at room temperature for 15 min, followed 
by inactivation using 2 mM EDTA (Ambion) at 65°C for 10 min. The concentration 
and purity was evaluated using the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies). Three hundred ng of RNA was reverse transcribed using 
the high-capacity cDNA Reverse Transcription Kit (Applied Biosciences). The cDNA 
was either used immediately for qRT-PCR reactions or stored at -20°C until use. 
Because of limited material availability the cDNA was preamplified. Preamplification 
was performed for 14 cycles using TaqMan® PreAmp Master Mix Kit (Applied 
Biosystems). All kits were used according to the manufacturer’s instructions. 
 
Real-time quantitative reverse transcription–polymerase chain reaction (qRT-
PCR) 
The expression of target genes was analyzed using TaqMan® gene expression 
assays containing commercially available predeveloped TaqMan reagents with 
optimized primer and probe concentrations and TaqMan 1x universal master mix 
(Applied Biosystems) (Supplementary Table S2), on a RotoGene Q real-time PCR 
cycler (Qiagen). The reaction mixture (10 µL) consisted of 1 µL cDNA, 3.5 µL water, 
0.5 µL primer and 5 µL TaqMan 1x universal master mix. The following cycle 
conditions were used: initial hold for 2 min at 50°C and 10 min at 95°C the probes 
were cycled 45 times at 95°C for 15 sec and at 60°C for 1 min. All reactions were 
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performed in at least triplicates. Threshold cycle (Ct) values were determined using 
the Rotor-Gene Q Series software 1.7. ΔCt levels of the transcripts were calculated 
by normalization to the endogenous control (β-actin). The change in expression 
(ΔΔCt) levels of the target genes following radiotherapy is given as the fold change in 
expression (2- (ΔΔCt)) and is determined as [ΔCt before radiotherapy - ΔCt after radiotherapy]. Ct 
values >38 cycles were interpreted as negative for gene expression. Fold changes in 
the range of a fold increase of >0.5 and <2 was considered as not significant. This 
range is marked as shaded area in the figures.  
 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on FFPE paired tissue sections 
obtained from a cohort of 37-38 sarcoma patients. Sections were stained with mouse 
anti-human monoclonal antibodies against CD4 (clone 1F6, 1:30, ZYMED 
Laboratories Inc.), CD8 (clone C8/114B, 1:100, DAKO A/S), MHC-I (clone C21, 
1:1000, RDI Research Diagnostics, Inc.), CD3 (clone F7.2.38, 1:50, Dako), CT7 
(clone CT7-33, 1:80, DAKO A/S), NY-ESO-1 (clone E978, 1:50, ZYMED). Sections 
were counterstained with hematoxylin, dehydrated and mounted. All sections were 
processed with the Ventana Benchmark automated staining system (Ventana 
Medical Systems) using Ventana reagents for NY-ESO-1, CT7, CD4, CD8 and CD3 
and the BondMax (Vison BioSystems) for MHC-I. UView (Ventana) or Refine DAB 
(Vision BioSystems) were used as chromogens against the primary antibodies. The 
slides were scanned on a NDP.view2 software (Hamamatsu), and analyzed using 
the IHC analysis software (NDP.analyze, Hamamatsu). The fields were observed at 
a magnification of × 200 (field of view = 493.1 × 368.5 μm−1). The IHC analysis was 
performed by counting 10 random fields. The staining was scored on a scale of 0 to 5 
for the expression of NY-ESO-1 and MAGE-C1/CT7 as a percentage, based on the 
number of positive cells expressing the antigen to the total number of cells in a high-
Research. 
on August 14, 2013. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 16, 2013; DOI: 10.1158/1078-0432.CCR-13-0352 
 8
power field (HPF). The tumor infiltrates were calculated as the number of cells 
expressing CD3, CD4, and CD8 per HPF. The MHC-I sections were acquired on 
Zeiss-Axiovert 200M (Carl Zeiss Light Microscopy) inverse microscope using Carl 
Zeiss Axiovision CD28 imaging system.  The scoring for MHC-I expression was done 
based on the intensity of staining (details in Supplementary Table S3). Two 
individuals performed the scoring blindly and independently for MHC-I and one 
individual performed the scoring blindly for the other stainings. The IHC staining was 
interpreted in conjunction with a single haematoxylin and eosin (H&E) stained slide 
by a pathologist (BB). The malignant nature of the tumors for the IHC evaluation and 
qRT-PCR analysis was apparent from the H&E stained slides. 
 
Statistical analysis and heatmaps 
Correlations between the different immune response related transcripts was 
assessed using the Spearman`s rho correlation coefficient (ρ) and the significance-
two tailed analysis (P value) was used to analyse the statistical significance (IBM 
SPSS statistics software). The dot plots for all significant correlations were generated 
using the Graphpad-Prism software. Statistical significance was defined as P < 0.05. 
 For visualizing the gene expression profile in the sarcoma patients following 
radiotherapy, heatmaps were generated using Software: R, Bioconductor library 
“gplots”, heatmap.2 software. Subtracting the mean expression value across patients 
centered the values for each transcript. No gene-specific scaling (standardization) 
was done, so that the information about the relative signal strength between probes 
remained intact. The color tone in the heatmaps was calibrated, so that saturated red 
(upregulation) and saturated green (downregulation) were reached at values equal to 
three times the standard deviation of the expression values of the entire matrix. 
Heatmaps were created for all the patients using the ΔΔCt values [ΔCt before radiotherapy - 
ΔCt after radiotherapy]. For the purpose of clustering the genes, the de novo expression 
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was assigned a ΔΔCt value of -10 and the loss of expression was assigned a ΔΔCt 
value of +10. A hierarchical clustering method using Software: R, Bioconductor 
library “gplots”, heatmap.2 software was used to group genes on the basis of similar 
expression patterns, in relation to their survival status (green indicates similar 
behavior of genes and red indicates the reverse). Statistical analysis was performed 
for each transcript between the cohort before and after radiotherapy using the two-
tailed bivariate analysis (P value) (Graphpad-Prism) on the ΔCt values after 
normalization to β-actin.  
 
RESULTS 
 
Radiotherapy results in upregulation of transcripts of several immune effector 
molecules and CT-antigens and downregulation of transcripts associated with 
immune suppression in sarcoma patients  
To understand the immunomodulatory effects of radiotherapy in sarcomas, we 
retrospectively analyzed the expression of several immune response-related 
transcripts and CT-antigens (Supplementary Table S2) by qRT-PCR analysis on 
paired formalin-fixed paraffin-embedded (FFPE) tumor tissues from 37 sarcoma 
patients before and after radiotherapy (Table 1). We observed that radiotherapy 
resulted in upregulated transcripts specific for several immune effector cells or 
proteins including CD45, CD3, CD4, CD8, MHC-I, MHC-II, perforin, granzyme B, 
IFN-γ, IL-12 and NKG2D in most patients. Additionally, we observed de novo 
expression of perforin, NKG2D and iNOS in two or more patients. TNF-α transcripts 
were upregulated in several patients but downregulated in others. Concomitantly, the 
expression of various transcripts related to immune suppression (FoxP3, CD68, 
CD163, CTLA-4, arginase-1, IDO, PD-1, PD-L1, IL-10, TGF-β and BTLA) was 
downregulated in some patients but upregulated or unchanged in others. At least in 
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one of the patients the expression of FoxP3, PD-1, CTLA-4, BTLA or IL-10 was lost 
following radiotherapy (Fig. 1A and B, Table 2). Additionally, radiotherapy resulted in 
a substantial upregulation or de novo expression of one or more CT-antigens (CT7, 
LAGE-A1, MAGE-A9 and NY-ESO-1) (Fig. 1C, Table 2). As the fold change in 
expression in terms of de novo or loss of gene expression cannot be computed, the 
grand mean was calculated excluding these values. Our data suggest that 
radiotherapy results in a favourable upregulation of transcripts associated with 
effector function when compared to those associated with immune suppression, 
therefore indicating that radiotherapy may presumably promotes protective immunity 
in the tumor (Table 2 and Supplementary Fig. S4). 
 
Radiotherapy results in increased expression of CT-antigens, MHC-I and in 
lymphocyte infiltration at the protein level  
To validate our findings at the protein level we compared the expression of CT-
antigens, MHC-I as well as the infiltration of lymphocytes by immunohistochemistry in 
37-38 paired FFPE sections obtained from sarcoma patients before and after 
radiotherapy. Radiotherapy upregulated the expression of MHC-I in 30 of 38 patients 
(Fig. 2D) and resulted in an increased infiltration by CD4+ and CD8+ T lymphocytes 
(Fig. 2A-C, Table 3). Furthermore, radiotherapy resulted in a substantial upregulation 
or de novo expression of the CT-antigens NY-ESO-1 in 13 of 38 patients (Fig. 2E, 
Table 3) and of CT7 in 17 of 38 patients (Fig. 2F, Table 3). Interestingly, most of the 
patients with an upregulated expression of one or more CT-antigens had a 
concomitant upregulation of MHC-I and/or increased infiltration of T cells (patient 
number: 2, 3, 5, 7, 8, 9,10, 11, 15, 17,19, 20, 22, 23 25, 27, 31, 33, 34, 35, and 36), 
which approximately comprises 55.3% of the patients. Those changes following 
radiotherapy were significant when compared to the untreated samples 
(Supplementary Fig. S5). Due to limited availability of material, we could not perform 
staining for additional CT-antigens. We know from our previous work, that the 
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expression of CT-antigens is upregulated upon irradiation in different tumor types 
(17). Representative sections (Fig. 2G) illustrate that there is a difference in the 
degree of radiotherapy-induced changes between individual sarcoma patients. A 
particular gene may be homogeneously expressed after radiotherapy (lower panels), 
whereas its expression may be upregulated, but still heterogeneous in others (upper 
panels). The concomitant upregulated expression of MHC-I and CT-antigens upon 
radiotherapy may increase the visibility of the tumor for CD8+ T cells. 
 
Radiotherapy results in clustered changes in expression of genes associated 
with immune suppression or immune effector function. 
To investigate whether the changes we observed upon radiotherapy are part of a 
coordinated program we plotted our data as a heatmap by computing the ΔΔCt 
values of each of the transcripts against the ΔΔCt value of the other transcripts. 
Transcripts associated with immune suppression including IDO, BTLA, FoxP3, PD-
L1, IL-10, TGF-β, STAT-3, CT10, TNF-α and iNOS seem to follow a similar pattern of 
downregulated expression after radiotherapy. Furthermore, transcripts associated 
with immune effector function such as NKG2D, CD45, CD3, CD4, CD8, MHC-II, β2M, 
perforin, granzyme B, the CT-antigen CT7 and macrophages (CD68, CD163) seem 
to be upregulated in a coordinated fashion following radiotherapy (Fig. 3A).  In order 
to determine the significance of correlation between two target genes, the ΔΔCt 
values of each of the target genes were computed against the other using a two-
tailed bivariate analysis and the Spearman`s rho correlation coefficient. For 
mathematical reasons, we excluded patients with de novo expression or loss of 
expression following radiotherapy from the analysis. We found a positive correlation 
between several immune effectors and an inverse correlation between the transcripts 
of several immune effectors and immune suppressors. The scattered dot plots for the 
significant correlations are represented in Supplementary Figure S6. The 
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Spearman`s rho correlation coefficient for all the correlations is listed in the 
Supplementary Table S7.  
 
Radiotherapy results in downregulation of genes associated with immune 
suppression in sarcoma patients with prolonged survival 
To correlate the gene expression profile in sarcoma patients following radiotherapy in 
relation to their survival status, we plotted the change in expression (ΔΔCt) levels of 
the target genes following radiotherapy in a heatmap. We excluded the CT-antigen 
SSX-2 from this analysis, because it was expressed in only two tumor samples. All 
patients who survived for three or more years after radiotherapy, irrespective of the 
clinical outcome at the end of the follow up, formed one group.  Those who survived 
for less than three years after radiotherapy and were dead at the end of the follow up 
formed the other group. The heatmap reveals a clear downregulation of genes 
associated with immune suppression such as arginase-1, BTLA, CTLA-4, IDO, iNOS, 
PD-1, PD-L1, IL-10, TGF-β, TNF-α, FoxP3, macrophages (CD68, CD163) and CT10 
in samples of patients who survived for a period of three years or more after 
radiotherapy, but not in those who died. The immune effector genes followed a more 
homogenous pattern of expression independent of the survival status following 
radiotherapy (Fig. 4). 
 
DISCUSSION 
 
Radiotherapy is an integrated treatment option for sarcoma patients. For 
considerable time it was thought that radiotherapy may have immunosuppressive 
effects (20), however evidence from recent animal studies suggests that radiotherapy 
supports local anti-tumor immunity (18, 21, 22). The current study demonstrates in 
human sarcoma patients that radiotherapy indeed changes the local tumor 
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microenvironment from immunosuppressive into one that is reminiscent of protective 
immunity. We compared the immune infiltrate in paired biopsies from 38 human 
sarcoma patients collected before and after radiotherapy and found that radiotherapy 
induced remarkable changes, all of which suggest a skewing towards protective 
effector immunity. The activation of CD8+ T and CD4+ T cells contributes to anti-
tumor immunity (23, 24) and is also known to facilitate the efficacy of radiotherapy 
(25, 26); this is clearly supported by a higher tumor incidence in immunosuppressed 
patients (27). We observed a higher infiltration of both CD4+ and CD8+ T cells in most 
of the sarcoma patients after radiotherapy. Additionally, we observed that 
radiotherapy resulted in an upregulated expression of MHC-I and of different CT-
antigens in most sarcoma patients, which makes tumors more visible to CD8+ T cells. 
These data are in accordance with published data showing that non-lethal doses of 
radiation induce a dose-dependent increase of MHC-I (28) and CT-antigens resulting 
in better recognition by specific CD8+ T cells in vitro (17). Importantly, radiotherapy 
sometimes changed the heterogeneous expression of MHC-I and/or CT-antigens, 
which is thought to result from immune escape (3, 29), to a homogeneous 
expression, thus enabling a more complete surveillance of the tumor. In addition to 
changes that improve immunological visibility of tumor cells, we also detected de 
novo expression of the highly immunogenic CT-antigens in some patients as a result 
of radiotherapy; this is well in line with our previous data (17). The observed changes 
are relevant as the loss of MHC-I expression in the equilibrium phase is thought to 
contribute to escape from immune control leading to tumor progression (30). 
The tumor microenvironment is often immunosuppressive, thereby failing to activate 
local immune responses (31). Several studies have described the roles of 
immunosuppressive cytokines such as TGF-β and IL-10 in aiding tumor progression 
and that of stimulatory cytokines such as TNF-α, IL-12 and IFN-γ in supporting anti-
tumor effects (32-36). We observed a higher expression of immune effector 
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molecules, including perforin, granzyme B, NKG2D, IFN-γ, TNF-α and IL-12, some of 
which were only expressed after radiotherapy in particular patients. At the same time 
many molecules and cell types associated with immunosuppression, including 
arginase-1, BTLA, CTLA-4, PD-1, PD-L1, IDO, FoxP3, macrophages, TGF-β and IL-
10 were expressed at lower level or even disappeared completely after radiotherapy. 
In search for immune parameters that predict the response to radiotherapy, we found 
that radiotherapy-induced downregulation of several immune suppressors correlated 
with survival status. In addition, the correlation analysis revealed that the transcripts 
associated with immune suppression (IDO, BTLA, FoxP3, PD-L1, IL-10, TGF-β and 
macrophages) have a similar pattern of expression. Also immune effectors such as 
NKG2D, CD45, CD3, CD4, CD8, MHC-II, β2M, perforin and granzyme B respond in 
a similar and presumably coordinated fashion upon radiotherapy. Despite the clinical 
heterogeneity in the cohort of sarcoma patients in our study, the response to 
radiotherapy was similar as were the changes in the immune infiltrate. 
The apparent immunostimulation of radiotherapy per se argues for combining this 
therapy with treatments that interfere with immunoregulation and/or enhance immune 
stimulation. There is evidence in humans and mice that local radiotherapy under 
CTLA-4 blockade results in tumor regression of non-irradiated tumors as well 
(abscopal effect) (37, 38). Similar results may be obtained when radiotherapy is 
combined with blockade of other co-inhibitory molecules, such as Tim-3, PD-1 or 
BTLA (39-41). A recent study has shown that anti–PD-1 antibody produced objective 
responses, one in four to one in five patients with advanced nonsmall cell lung 
cancer, melanoma, or renal-cell cancer (42). This obviously is a promising 
combination especially in the case of micro-metastases. Another option may be 
combination radiotherapy with the targeted delivery of immunostimulatory cytokines, 
which has been shown to synergize with chemotherapy in human and murine 
cancers (43, 44). A previous study reported, that a combination of radiotherapy with 
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IL-12 improves both local and distant tumor control compared to either therapy alone 
(45). Additionally, radiotherapy may create a favorable environment for adoptively 
transferred tumor-specific T cells (18, 46), which argues for combining adoptive T cell 
therapy and radiotherapy. Preclinical studies in carcinoembryonic antigen (CEA) 
transgenic mice and a murine carcinoma cell line transfected with CEA, on combined 
treatment with low-dose radiation and vaccine expressing CEA and co-stimulatory 
molecules, could show a 50% reduction in tumor growth and a massive trafficking of 
T cells, when compared to either treatment alone (47). A clinical trial in cancer 
patients, vaccinated with NY-ESO-1 DNA vaccine showed induction of antigen-
specific T-cell responses in 93% of vaccinated patients, however this did not lead to 
a clinical benefit (48). A recent study also showed that NY-ESO-1 OLP (overlapping 
long peptides) vaccine could rapidly induce integrated immune responses (antibody, 
CD8+ and CD4+) in nearly all vaccinated patients with advanced ovarian cancer, 
when administered with appropriate adjuvants (49). A Phase I clinical trial in HLA-
A2+ melanoma patients using immunization with autologous PBMCs pulsed with a 
MAGE-3 or a Melan-A peptide, increased specific CD8+ T-cell responses, and six out 
of eight patients had evidence of clinical activity (50). These studies show that on 
vaccination with a relevant CT-antigen the peripheral responses could be boosted in 
cancer patients, however they clearly do not show the desired anti-tumor efficacy. 
Therefore combining radiotherapy with immune stimulation may support the immune 
modulating potential of radiotherapy by interfering with the local immunosuppressive 
milieu. Future trials with a large cohort of patients are required to evaluate the 
question of clinical outcome and the safety of this combination. This may lead to new 
concepts in the clinical management of cancer. 
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Figure Legends 
 
Figure 1. Radiotherapy-induced changes of immune response-related gene 
expression in human sarcoma. Thirty-seven paired FFPE sarcoma samples 
before/after radiotherapy were subjected to qR-PCR analysis for 35 different immune 
response-related genes. (A) Immune cells (B) Cytokines and (C) Cancer Testis 
antigens. ΔCt levels of the transcripts were calculated by normalization to the 
endogenous control (β-actin). Results are presented as fold change in expression (2- 
(ΔΔCt)), which was determined as [ΔCtbefore radiotherapy - ΔCtafter radiotherapy]. Genes displayed 
on the left side of the vertical dotted line are associated with immune effectors and 
those on the right with immune suppressors. Fold differences in expression within the 
shaded area are considered as not significant. The bold horizontal line for each 
transcript represents the grand mean. Each symbol represents an individual patient. 
 
Figure 2. Radiotherapy of human sarcoma results in increased expression of 
Cancer Testis antigens and MHC-I and promotes infiltration by lymphocytes. 
Paired FFPE tissue sections from sarcoma patients (n = 37-38) before and after 
radiotherapy were analyzed by IHC for (A) expression of MHC-I, infiltration of (B) 
CD3+ (C) CD4+ (D) CD8+ cells, expression of (E) NY-ESO-1 and (F) CT7. Scores of 
individual patients before (open symbols) and after (closed symbols) radiotherapy 
are connected with a line. Details to scoring are described in Materials and Methods 
and are listed in Supplementary Table S3. (G) Representative staining of paired 
samples before (NR) and after (RT) radiotherapy for MHC-I, CD3, CD4, CD8, CT7 
and NY-ESO-1.  
 
Figure 3. Correlation between different immune response-related transcripts 
following radiotherapy in sarcoma patients (A) Heatmap demonstrating the 
correlation pattern of immune response-related transcripts in a cohort of paired 37 
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sarcoma patients following radiotherapy. The histogram indicates gene expression 
patterns from similar (green) to opposite (red). The white line demarks genes with a 
similar pattern of expression  
 
Figure 4. Correlation between radiotherapy-induced immunological changes in 
sarcoma patients and their survival status. Heatmap demonstrating the 
expression pattern of immune response-related transcripts in sarcoma patients 
following radiotherapy. The histogram indicates expression level (ΔΔCt values) from 
low (green) to high (red). The patients are divided into two groups (alive or dead), 
depending on the three-year survival status. Patients who were alive at the end of 
the follow up but did not reach the three-year survival mark yet were excluded. The 
yellow box demarcates a clear difference in gene expression between the alive and 
dead patients. 
 
Table 1. Patient information. The table summarizes patient diagnosis, cumulative 
dose of radiation, percentage of cells alive following radiotherapy and the survival 
status. All patients received only radiotherapy (RT) and underwent surgery as part of 
their standard treatment regimen. N: number of patients, MPNST: malignant 
peripheral nerve sheath tumor, NOS: not otherwise specified.  
 
Table 2. Summary of radiotherapy-induced changes in immune response-
related transcripts in human sarcomas. A retrospective qRT-PCR analysis of 
transcripts for (A) immune cells (B) cytokines (C) transcription factors and (D) CT-
antigens. ND: not determined, N: number of patients. 
 
Table 3.  Summary of radiotherapy-induced changes in infiltration by T cells 
and expression of MHC-I, CT7 and NY-ESO-1 in human sarcomas. IHC analysis 
of a cohort of paired tumor samples before/after radiotherapy of 37-38 sarcoma 
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patients for T cells, MHC-I, CT7 and NY-ESO-1. ND: not determined, N: number of 
patients. 
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Diagnosis N
Angiosarcoma 1
Leiomyosarcoma 4
MPNST 2
Myxofibrosarcoma 3
Myxoid liposarcoma 10
Pleomorphic liposarcoma 2
Pleomorphic sarcoma NOS 10
Pleomorphic sarcoma with Rhabdomyosarcoma 1
Rhabdomyosarcoma 1
Synovial sarcoma 2
Sclerosing epithelial fibrosarcoma 1
Spindle cell sarcoma with pleomorphic Liposarcoma 1
RT dose (Gy) N
!" #
$" %$
&' #
&!(& #
&" %
)*+*,-* '
% cells alive following RT N
  < 5 2
  5 - 10 4
 11 -  20 5
 21 - 30 3
 31 - 40 0
 41 - 50 2
 51 - 60 1
 61 - 70 2
 71 - 80 6
 81 - 90 5
 > 90 2
 Unknown 6
Survival status following RT N
./012 %"
3245 #"
)*+*,-* '
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up-regulation (N) ! down-regulation (N) % de novo (N) % loss of expression (N) % no change (N) % ND (N) % N
A Immune cells
"#$% &' %&($ ) *(& + +(+ + +(+ &% $+(% + +(+ ),
"#) &' %&($ ) *(& + +(+ + +(+ &% $+(% + +(+ ),
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/0"122 &' %&($ - %($ + +(+ + +(+ &. $)(- + +(+ ),
β2 microglobulin -+ %$(& - %($ + +(+ + +(+ &% $+(% + +(+ ),
34567589 -& %.(* $ &+(* - %($ + +(+ ' -$() & -(, ),
Granzyme B &) )%(& $ &+(* + +(+ + +(+ ' -$() && -'(, ),
iNOS . &.(- * -&(. - %($ + +(+ . &.(- &% $+(% ),
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B Cytokines
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up-regulation (N) % down-regulation (N) % de novo expression (N) % loss of expression (N) % no change (N) % ND (N) % N 
A Immune cells
CD3 26 70.3 1 2.7 0 0.0 0 0.0 10 27.0 0 0 37
CD4 34 89.5 2 5.3 0 0.0 0 0.0 2 5.3 0 0 38
CD8 26 68.4 1 2.6 0 0.0 0 0.0 11 28.9 0 0 38
B MHC-I 30 78.9 0 0.0 0 0.0 0 0.0 8 21.1 0 0 38
C CT-antigens
CT7 8 21.1 1 2.6 9 23.7 0 0.0 8 21.1 12 !"#$ 38
NY-ESO-1 8 21.1 1 2.6 5 13.2 0 0.0 8 21.1 16 %&#" 38
Table 3
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